Moderna IncNASDAQ:MRNA
- LAST PRICE62.4500
- TODAY'S CHANGE (%)-0.7100 (-1.1241%)
- Bid / Lots62.3500/ 2
- Ask / Lots62.4600/ 1
- Open / Previous Close62.5300 / 63.1600
- Day Range
- 52 Week Range
- Volume290,191
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MRNA |
|---|---|---|
| 09:32 ET | 79691 | 62.82 |
| 09:34 ET | 14133 | 62.81 |
| 09:36 ET | 65494 | 62.53 |
| 09:38 ET | 25485 | 62.735 |
| 09:39 ET | 11774 | 62.425 |
| 09:41 ET | 8954 | 62.45 |
Today
Yesterday
October 8, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MRNA, from 21 hours ago by Dow Jones
21 hours ago by Dow JonesMRNA LAWSUIT ALERT: Levi & Korsinsky Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline, from 22 hours ago by Dow Jones
22 hours ago by Dow JonesThe Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Moderna, Inc., from 22 hours ago by Dow Jones
22 hours ago by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Moderna Inc | 24.3B | -4.1x | --- |
ICON PLC | 24.4B | 34.2x | +4.68% |
Biontech SE | 28.3B | -51.4x | --- |
Biogen Inc | 27.5B | 23.5x | -18.14% |
Grifols SA | 7.1B | 36.0x | --- |
Beigene Ltd | 26.3B | -46.4x | --- |
Company Information
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Contact Information
- Headquarters
- 325 BINNEY STREETCambridge, MA, United States 02142
- Phone
- 617-714-6500
- Fax
- 617-583-1998
Executives
- Non-Executive Independent Chairman of the Board, Co-Founder
- Noubar Afeyan
- President
- Stephen Hoge
- Chief Executive Officer, Director
- Stephane Bancel
- Chief Financial Officer
- James Mock
- Chief Technical Operations and Quality Officer
- Jerh Collins
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.3B |
|---|---|
Revenue (TTM) | $5.1B |
Shares Outstanding | 384.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.67 |
EPS | $-15.37 |
Book Value | $36.27 |
P/E Ratio | -4.1x |
Price/Sales (TTM) | 4.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -91.78% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
